AI enabled therapeutic antibody discovery against age related cancer types. 1 antibody against 4 age related cancer types.
Regenova Pharmaceuticals Inc.
Project Summary
Regenova’s initial project focuses on the development of a therapeutic antibody targeting cancer stem cells across multiple age-related cancers. The program aims to design a single antibody capable of addressing shared biological pathways in multiple tumor types, improving efficiency in drug development. The project will advance through computational design, in-vitro validation, and early preclinical studies.
In parallel, the company is developing a Nipah virus antibody program aligned with global health priorities and regulatory pathways that enable accelerated development and potential PRV-based monetization. The goal of this funding is to generate validated antibody candidates and position programs for further preclinical and partnership-driven advancement.
Data Source Notes
Regenova Pharmaceuticals is an early-stage biotechnology company developing antibody therapeutics using a proprietary AI-driven discovery platform (TRACE). Information provided reflects internal company data, ongoing research programs, and strategic development plans. The company is currently advancing antibody candidates in oncology and infectious diseases, including Nipah virus.
Data is based on internal modeling, early experimental validation, and planned collaborations with academic and research institutions. Funding projections and timelines are aligned with current pre-seed fundraising and non-dilutive grant strategies.
Research Overview
Regenova Pharmaceuticals is focused on the discovery and development of therapeutic antibodies targeting oncology and infectious diseases. The company leverages its TRACE platform to design and optimize antibodies with improved binding affinity, specificity, and developability. Current programs include a multi-target oncology antibody designed to address cancer stem cells across multiple age-related cancers, as well as a Nipah virus antibody program aligned with global pandemic preparedness priorities. The approach integrates computational modeling with experimental validation to accelerate early-stage drug discovery and reduce downstream development risk.
Research Scale
Regenova operates as a lean, early-stage biotechnology company with a focused R&D model. Research activities are conducted through a combination of internal computational work and external collaborations with academic institutions and contract research organizations. The company prioritizes capital efficiency by advancing high-value programs to key inflection points before pursuing larger funding or partnerships. Current scale supports multiple parallel antibody programs with plans to expand research capacity through grant funding and strategic hires.
Research Strengths
Regenova’s primary strength lies in its ability to rapidly generate and evaluate antibody candidates using an integrated quantum AI and experimental workflow. The platform enables identification of high-affinity binders with favorable developability characteristics early in the discovery process. The company also focuses on high-impact disease areas, including oncology and emerging infectious diseases, where there is strong unmet need and clear regulatory pathways. Its asset-driven strategy allows for flexible monetization through licensing, partnerships, and priority review voucher opportunities.
Clinical Capabilities
Regenova does not currently operate internal clinical trial infrastructure but is structured to advance programs through external partnerships and contract research organizations. The company’s strategy is to progress candidates through preclinical and IND-enabling stages, followed by collaboration with clinical partners for trial execution. This approach enables efficient resource utilization while maintaining focus on early-stage innovation and asset development.
Interdisciplinary Research Areas
Regenova integrates multiple disciplines including computational biology, immunology, structural biology, Quantum Physics and data science. This interdisciplinary approach supports rapid antibody design and optimization while improving prediction of efficacy and developability.
Notable Research Centers and Institutes
Regenova collaborates with academic institutions and research programs, including connections through Johns Hopkins University and regional biotechnology ecosystems in Maryland. These collaborations support experimental validation and translational development.
Research Output
The company has generated multiple antibody candidates across oncology and infectious disease targets. Early outputs include computationally designed antibodies with predicted binding and initial validation data. Programs are advancing toward in-vitro and in-vivo validation stages.
Partnerships & Funding History
Industry Collaboration
Regenova is building relationships with academic institutions, research organizations, and potential biopharma partners like CancerFree bio and Chan Soong Institute of Molecular medicine. The company also aligns with global health initiatives focused on emerging infectious diseases.
The company is in long term collaboration agreement with CancerFree Bio and in early-stage discussions for potential collaborations with mid-sized biotech and pharmaceutical companies for co-development of antibody programs.
Current Collaboration
Current collaborations include academic and research partnerships supporting antibody validation and translational development including key collaborators CancerFree Bio and Chan Soon Institute of Molecular medicine.
Pharma Research Funding Presence
Regenova is currently pre-revenue and funded through early-stage capital through Johns Hopkins University grants and TEDCO concept capital funding and pursuing additional funding through venture investment and non-dilutive grants.
Major Research Funding Source
TEDCO
NIH Funding History
No prior NIH funding; the company plans to pursue NIH and related funding mechanisms for infectious disease programs.
